Abstract 99P
Background
Patients with chemotherapy-responsive advanced biliary tract cancer (BTC) are usually observed post 6 months of gemcitabine-based therapy, though most progress within a short time-span and there is limited prospective evidence for maintenance strategies.
Methods
The study is an integrated phase II – III randomised clinical trial (Clinical Trial Registry of India number: CTRI/2017/10/010112) conducted at 2 centres in India. Eligible patients with advanced BTC who had responsive or stable disease status post 6 months of gemcitabine – based chemotherapy were randomly assigned (1:1) to either observation arm (O) or intervention arm (BEER), which was a combination of Bevacizumab 5 mg/m2 IV every 21 days plus erlotinib 100 mg once daily, . Both arms were continued till disease progression, significant toxicity or patients choice. The primary endpoint of the phase II component was progression free survival, measured from randomization into the trial.
Results
Between May 2021 and November 2022, 98 patients (O: 48; BEER: 50) comprising 78 patients with gallbladder cancer (GBC) and 20 patients with cholangiocarcinoma (CC) were randomised with all 98 patients included in the final analysis. With a median follow up of 11.2 months, patients in the BEER cohort showed an improved PFS compared to the observation cohort [5.2 months (95% CI: 3.4-6.9) vs. 3 months (95% CI: 2.5 - 3.5); p=0.004]. The CC cohort tended to derive greater benefit from BEER (6.7 months vs. 2.2 months) than the GBC cohort (4.3 months vs. 3 months). There were no grade 3 or grade 4 adverse events noted, though temporary cessation of erlotinib was required due to grade 2 skin rash in 7 patients (14%), and grade 2 oral stomatitis in 1 patient (2%).
Conclusions
The combination of bevacizumab and erlotinib improves progression free survival in patients with chemotherapy responsive advanced BTC in this phase 2 clinical trial. The ongoing phase III component of the study will evaluate whether the significant benefit in PFS translates to improvement in overall survival.
Clinical trial identification
CTRI/2017/10/010112.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cadilla Pharma Pvt Ltd (supported bevacizumab) Dr. Reddy's Lab pvt Ltd (supported bevacizumab) LUPIN Pharma pvt Ltd Intas pvt Ltd.
Disclosure
A. Ramaswamy: Financial Interests, Institutional, Research Grant: Cipla Health Limited, Dr Reddy Laboratories, Zydus Lifesciences. V.S. Ostwal: Financial Interests, Institutional, Funding, IIS: Cadilla Pharmaceuticals pvt Lts, Reddy's pvt Ltd, Lupin, BDR; Financial Interests, Personal, Invited Speaker, GI ESMO 22: AstraZeneca; Financial Interests, Institutional, Advisory Board: Mankind, Natco. All other authors have declared no conflicts of interest.
Resources from the same session
690P - Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study
Presenter: Manish R Patel
Session: Poster session 17
691P - Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors
Presenter: John Strickler
Session: Poster session 17
692P - First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors
Presenter: Wen wee Ma
Session: Poster session 17
693P - Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models
Presenter: Yongqiang Shan
Session: Poster session 17
694P - Full efficacy analysis of phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy in refractory solid tumors
Presenter: Petri Bono
Session: Poster session 17
695P - A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti–PD-1) in patients (pts) with solid tumors or lymphoma
Presenter: Elena Garralda
Session: Poster session 17
696P - SIM1811-03 (SIM0235), an anti-tumor necrosis factor receptor-2 (TNFR2) monoclonal antibody, in patients with advanced solid tumor and/or cutaneous T cell lymphomas (CTCL): Preliminary results from an on-going first-in-human phase I trial in China
Presenter: Furong Liu
Session: Poster session 17
699P - Immunogenicity and reactogenicity of BNT162b2 COVID-19 mRNA vaccine in long-survivor (LS) patients with metastatic lung cancer (mLC) after primary immunization (PV) and booster (BD): COVALENCE study
Presenter: Emanuele Vita
Session: Poster session 17